title: Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats.
abstract: In the present study, we investigated the effects of long-term treatment with the endothelin (ET) antagonist atrasentan, an ET(A)-selective antagonist, on whole body glucose metabolism and insulin signaling in a commonly used model of insulin resistance, the Zucker fatty rat. Zucker lean and fatty rats were maintained for 6 weeks on either control or atrasentan-treated water. Euglycemic-hyperinsulinemic clamps (4 mU/kg per minute) were performed at the end of the 6-week treatment on a subset of rats (n=10/treatment). In another subset (n=5/treatment), an insulin tolerance test was performed; liver and muscle tissues were harvested 10 minutes following the challenge for further analysis. Results of the clamps demonstrated that long-term atrasentan treatment significantly increased whole body glucose metabolism in fatty rats compared with vehicle control subjects. Insulin-induced insulin receptor substrate 1 tyrosine and protein kinase B serine phosphorylation were significantly reduced in the liver and muscle of fatty animals compared with their lean littermates. This reduction was overcome with atrasentan treatment in the liver but not in the muscle. There was no difference between lean and fatty animals, however, in insulin receptor substrate 1 and protein kinase B protein expression in the liver and muscle and no effect by atrasentan. In contrast, expression of the regulatory subunit of PI-3 kinase (p85alpha) was significantly increased in the liver but not in the muscle of fatty animals compared with their lean littermates and this was normalized to levels of lean animals with atrasentan treatment. These findings indicate that long-standing ET antagonism improves whole body glucose metabolism in Zucker fatty rats through improvements in insulin signaling in the liver. These results indicate that therapeutic ET antagonism may assist in correcting the insulin-resistant state.
authors.affiliation: Global Pharmaceutical Research and Development Division, Metabolic Disease Research, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Berthiaume
authors.forename: Christian J
authors.initials: CJ
authors.lastname: Carlson
authors.forename: Cristina M
authors.initials: CM
authors.lastname: Rondinone
authors.forename: Bradley A
authors.initials: BA
authors.lastname: Zinker
mesh_terms: D000818:Animals; D000077868:Atrasentan; D001794:Blood Pressure; D001835:Body Weight / Q000187:drug effects; D004326:Drinking / Q000187:drug effects; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000097:blood; D005947:Glucose / Q000378:metabolism; D015309:Glucose Clamp Technique; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D008099:Liver / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D011924:Rats, Zucker; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D019332:Endothelin-1; D007328:Insulin; D011759:Pyrrolidines; D005947:Glucose; D000077868:Atrasentan